From obstructive uropathy to syndromic suspicion: a case of multiglandular primary hyperparathyroidism and pancreatic nodule mimicking multiple endocrine neoplasia type 1
DOI:
https://doi.org/10.18203/2349-2902.isj20263011Keywords:
Primary hyperparathyroidism, Multiple endocrine neoplasia type 1, Pancreatic neuroendocrine tumor, Multiglandular parathyroid disease, Obstructive uropathy, Staghorncalculi, Technetium-99m sestamibi SPECT-CT, 68Ga-Trivehexin PET-CTAbstract
Multiple endocrine neoplasia type 1 (MEN-1) is an autosomal dominant disorder characterized by synchronous or metachronous tumor development within the parathyroid glands, enteropancreatic neuroendocrine framework, and anterior pituitary. A 48-year-old female presented with severe bilateral loin pain and anuria lasting 1 month. Comprehensive imaging revealed bilateral hydroureteronephrosis from staghorn and renal calculi requiring urgent bilateral double-J (DJ) stenting. Subsequent endocrine evaluations demonstrated hyperparathyroidism (PTH: 191.9 pg/ml). Targeted 99mTc-Sestamibi SPECT-CT and 68Ga-Trivehexin PET-CT localized multiple hyperfunctioning parathyroid adenomas. Systemic staging via MRCP identified an additional 1.7 cm cystic neuroendocrine tumor within the uncinate process of the pancreas, structurally mimicking a classic MEN-1 phenotypic cluster. The clinical constellation of multiglandular parathyroid adenomas/hyperplasia combined with a cystic neuroendocrine tumor of the pancreatic uncinate process presents a classic phenotypic presentation mimicking MEN-1 syndrome (Wermer's syndrome).While the pituitary MRI was completely unremarkable at this stage, the coexistence of primary hyperparathyroidism and a suspicious pNET strongly mandates long-term genetic screening (MEN-1 gene mutation analysis) and close clinical surveillance. The patient's acute obstructive uropathy has been successfully managed via bilateral DJ stenting, and metabolic control has been targeted via targeted parathyroidectomy.
References
Thakker RV, Newey PJ, Walls GV, Bilezikian J, Dralle H, Ebeling PR, et al; Endocrine Society. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012;97(9):2990-3011.
Turner JJ. MEN1 phenocopies: a clinical and genetic review. Ther Adv Endocrinol Metab. 2018;9(4):113-24.
Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C, et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab. 2014;99(10):3561-9.
Al-Salameh A, Cadiot G, Calender A, Murat A, Goudet P, Beckers A, et al. Clinical aspects of multiple endocrine neoplasia type 1. Nat Rev Endocrinol. 2021;17(4):207-24.
Wong KK, Sisson JC, Kaza RK, Lauterbach SJ, Miller BS, Gauger PG, et al. 99mTc-Sestamibi SPECT/CT localized parathyroid adenomas: a radiological and nuclear medicine timeline. AJR Am J Roentgenol. 2015;204(6):W700-8.
Lamberts SW, Hofland LJ. Molecular imaging of neuroendocrine tumors: the expanding role of target-specific PET tracers. Endocr Rev. 2019;40(6):1421-40.